Tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy) are different molecules with different mechanisms. This guide explains the key differences in mechanism, weight loss data, side effects, and brand names.
Tirzepatide and Ozempic are different molecules. Ozempic (semaglutide) targets only the GLP-1 receptor. Tirzepatide (Mounjaro/Zepbound) targets both GLP-1 and GIP receptors — the dual mechanism produces greater weight loss. Clinical data shows tirzepatide outperforms semaglutide by approximately 7 percentage points of body weight lost.
| Feature | Semaglutide (Ozempic) | Tirzepatide (Mounjaro) |
|---|---|---|
| Mechanism | GLP-1 agonist | GLP-1 + GIP dual agonist |
| Mean weight loss | ~15% (STEP 1, 68 wks) | ~22% (SURMOUNT-1, 72 wks) |
| Max approved dose | 2.4 mg/wk (Wegovy) | 15 mg/wk (Zepbound) |
| Half-life | ~7 days | ~5 days |
| Cardiovascular data | Yes (FLOW trial) | Yes (SURPASS-CVOT) |
| PCOS evidence | Moderate | Strong |
| GI side effects | Common (30–44% nausea) | Common (25–45% nausea) |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Research grade available | Yes (Purgo Labs) | Yes (Purgo Labs) |
No. Tirzepatide and Ozempic (semaglutide) are different molecules. Ozempic is a GLP-1 receptor agonist. Tirzepatide is a dual GLP-1 and GIP receptor agonist — it targets two receptors instead of one. Tirzepatide is sold under the brand names Mounjaro (for type 2 diabetes) and Zepbound (for weight management) by Eli Lilly.
Clinical trial data shows tirzepatide produces greater weight loss than semaglutide. SURMOUNT-1 showed tirzepatide produced ~22% mean weight loss at 72 weeks. STEP 1 showed semaglutide produced ~15% at 68 weeks. Head-to-head data from SURPASS-CVOT shows tirzepatide outperforms semaglutide on weight loss endpoints.
All three are tirzepatide. Mounjaro is the brand name approved for type 2 diabetes management. Zepbound is the brand name approved for chronic weight management. Both are manufactured by Eli Lilly. Research-grade tirzepatide is the same molecule available for research purposes.
Both have similar GI side effect profiles (nausea, vomiting, diarrhea, constipation). Tirzepatide may have slightly higher rates of nausea at therapeutic doses due to the dual receptor mechanism, but the difference is modest. Both are well-tolerated with slow titration.
FDA-approved Mounjaro and Zepbound require a prescription. Research-grade tirzepatide is available from research chemical suppliers like Purgo Labs for research purposes only. It is not sold for human consumption and is not a substitute for prescription medication.
Purgo Labs provides pharmaceutical-grade tirzepatide with third-party COAs. Use code HEALTH for 15% off your first order.
Buy Tirzepatide at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.